Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

110
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
110
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

657
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
657
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

687
The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
687

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and validation of the first needs-based quality of life measure for individuals with manifest Huntington's disease.

Journal of neurology·2026
Same author

A Two-Track Model of Huntington's Disease Pathology: Striatal Atrophy Mediates Maladaptive Immune Dysregulation.

International journal of molecular sciences·2026
Same author

Shape matters: Predicting Huntington's disease using progression modelling.

Computer methods and programs in biomedicine·2026
Same author

Falls and Injuries Resulting from Falls among Patients with Parkinsonism: A Reappraisal.

Movement disorders clinical practice·2026
Same author

Mapping Regional Brain Aging in Huntington's Disease Using Structural Magnetic Resonance Imaging and Machine Learning.

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

Discovery and Targeted Proteomic Studies Reveal Striatal Markers Validated for Huntington's Disease.

Annals of clinical and translational neurology·2025

Related Experiment Video

Updated: May 4, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

9.0K

Managing juvenile Huntington's disease.

Oliver W J Quarrell1, Martha A Nance2, Peggy Nopoulos3

  • 1Department of Clinical Genetics, Sheffield Children's Hospital, Sheffield, UK.

Neurodegenerative Disease Management
|January 14, 2014
PubMed
Summary

Huntington's disease (HD) is a progressive neurodegenerative disorder. Juvenile HD (JHD), defined as onset before age 20, presents distinct clinical and pathological features requiring specialized management strategies.

More Related Videos

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
11:47

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

10.1K
Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
10:52

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System

Published on: December 10, 2021

4.6K

Related Experiment Videos

Last Updated: May 4, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

9.0K
Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
11:47

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

10.1K
Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
10:52

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System

Published on: December 10, 2021

4.6K

Area of Science:

  • Neurology
  • Genetics
  • Neurodegenerative Diseases

Background:

  • Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder.
  • Onset typically occurs between 35-55 years, but onset ≤20 years defines juvenile HD (JHD).
  • JHD shares features with adult-onset HD but has distinct characteristics.

Purpose of the Study:

  • To review current knowledge of juvenile Huntington's disease (JHD).
  • To highlight the distinctions between JHD and adult-onset HD.
  • To provide management suggestions for JHD based on clinical experience.

Main Methods:

  • Literature review of Huntington's disease (HD) and juvenile HD (JHD).
  • Analysis of clinical, pathological, and genetic features differentiating JHD.
  • Synthesis of management strategies from clinical experience.

Main Results:

  • JHD exhibits early bradykinesia, dystonia, epilepsy, and myoclonus.
  • JHD often presents with more widespread pathology and larger genetic lesions.
  • Management of JHD is primarily symptomatic and supportive due to limited evidence-based guidelines.

Conclusions:

  • Juvenile HD (JHD) is a distinct subtype of Huntington's disease with unique clinical and pathological features.
  • The rarity of JHD necessitates tailored clinical approaches and further research.
  • Evidence-based guidelines for JHD management are critically needed.